Scarica l'app Stockscreener
27.20
8.20%
-2.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$29.56
Aprire:
$27.57
Volume 24 ore:
12.57M
Relative Volume:
1.18
Capitalizzazione di mercato:
$10.52B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.1157
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-20.54%
1M Prestazione:
-5.42%
6M Prestazione:
-31.16%
1 anno Prestazione:
-71.18%
Intervallo 1D:
$26.56
$27.88
Intervallo di 1 settimana:
$26.56
$34.70
Portata 52W:
$23.15
$91.99
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.20 | 12.43B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.80 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.39 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.11 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.44 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.35 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna: Q2 Earnings Snapshot - The Washington Post
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win - Reuters
Why Moderna (MRNA) Stock Is Trading Lower Today - Yahoo Finance
Moderna would provide Merck an M&A booster - TradingView
Moderna Cuts Outlook And Jobs As Vaccine Sales Wane - Finimize
Moderna Fights Off Pfizer Challenge To Surviving mRNA IP - Law360
Moderna (MRNA) Shares Plummet Amid Revenue Forecast Cut - GuruFocus
Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector - inkl
Moderna slashes full-year sales outlook, announces headcount reduction - Proactive financial news
Moderna slips 9% on layoffs, guidance - breakingthenews.net
Moderna Wins UK Patent Battle Against Pfizer and BioNTech - BioSpace
Earnings call transcript: Moderna Q2 2025 beats forecasts, stock dips - Investing.com Australia
Moderna’s Bancel Nay on M&A, Yay on R&D Partnerships - BioSpace
Moderna Stock Is Falling After Earnings. Guidance Is a Worry. - Barron's
Moderna Stock Drops as Firm Cuts Revenue Outlook on UK Vaccine Deliveries Delay - Yahoo Finance
Moderna (MRNA) Surpasses Revenue Expectations in Q2 - GuruFocus
Apple, Amazon, Figma, MicroStrategy, Coinbase, Reddit, Moderna, Fluor, and More Movers - Barron's
Earnings call transcript: Moderna Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com India
Moderna Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Moderna falls as cost-cutting fails to appease investors - The Detroit News
Moderna 2025 Q2 Earnings Narrowed Losses with Net Income Improvement - AInvest
Moderna CEO Attributes Full-Year Revenue Guidance Reduction To Timing Of Shipments: Retail Pins Hopes On Pipeline After Q2 Beat - Stocktwits
Earnings live: Exxon, Chevron oil output boosts profits, Moderna stock tumbles, Amazon sinks - Yahoo Finance
Moderna (MRNA) Wins Court Ruling Against Pfizer and BioNTech in Patent Dispute - GuruFocus
Moderna to Cut 10% of Global Workforce - Contract Pharma
Moderna to lay off 10 percent of its workforce - CBS News
Why Is Moderna Stock Falling Friday?Moderna (NASDAQ:MRNA) - Benzinga
Pfizer/BioNTech lose appeal to reverse Moderna’s COVID vaccine patent win in U.K. - Seeking Alpha
Moderna Falls as Cost-Cutting Fails to Appease Investors - MSN
Moderna drops after narrowing 2025 revenue outlook - MSN
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Moderna (MRNA) Exceeds Expectations Despite Challenges - GuruFocus
Flu RNA Vaccines Market Set to Witness Significant Growth - openPR.com
Moderna stock drops after Q2 2025 results (MRNA:NASDAQ) - Seeking Alpha
Exxon Mobil, Eli Lilly, Moderna - TradingView
Earnings Snapshot:Moderna surpasses estimates;cutsFY top-end rev outlo - Seeking Alpha
Moderna, Inc Q2 Loss Decreases, Beats Estimates - Nasdaq
Moderna Inc Q2 2025 Earnings: EPS Loss of $(2.13) Beats Estimate, Revenue of $142M Exceeds Forecast - GuruFocus
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates | MRNA Stock News - GuruFocus
Moderna (NASDAQ:MRNA) Exceeds Q2 Expectations But Stock Drops - Yahoo Finance
Moderna Stock Falls Again Amid Lowered Guidance, Job Cuts - inkl
Moderna's Q2 revenue slumps 41% to $142 million - breakingthenews.net
Moderna lowers top end of revenue guidance as vaccine group targets cost cuts - Investing.com Canada
Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts - Reuters
Moderna Q2 2025 slides: Revenue falls 41% as cost-cutting accelerates By Investing.com - Investing.com South Africa
Moderna Logs Sales Beat Despite Declining Vaccine Demand - The Wall Street Journal
Moderna’s Loss Narrows After Cost-Cutting Efforts Take Hold (MRNA) - Bloomberg
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Pfizer losses appeal in Moderna patent case - breakingthenews.net
Pfizer and BioNTech lose appeal in Moderna COVID vaccine patent case - Investing.com Canada
UK Court of Appeal Confirms Moderna's EP'949 Patent is Valid and Infringed by Pfizer/BioNTech | MRNA Stock News - GuruFocus
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.37%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):